Detailed Pipeline Analysis of the Key Osteoarthritis Products in Development, Plus Indication-Specific Drug Sales Forecasts to 2015.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c49689) has announced the addition of "Pipeline Insight: Osteoarthritis osteoarthritis or osteoarthrosis or degenerative joint disease Most common joint disorder, afflicting over 80% of those who reach age 70. It does not involve excessive inflammation and may have no symptoms, especially at first. - The Wait for a DMOAD DMOAD Disease-Modifying Osteoarthritis Drug(s) Continues" to their offering. Osteoarthritis (OA) is characterized by the progressive destruction of articular articular /ar·tic·u·lar/ (ahr-tik´u-ler) pertaining to a joint. ar·tic·u·lar adj. Of or relating to a joint or joints. articular pertaining to a joint. joints and is a major cause of pain in Western populations. Osteoarthritis is the most common form of arthritis and severely impacts the physical function and day-to-day quality of life of an individual. It also impacts heavily on the economy and it is believed to cost the US alone an estimated $60 billion per year. Scope of this title: - Detailed pipeline analysis of the key osteoarthritis products in development, plus indication-specific drug sales forecasts to 2015 - Competitive drug analysis of the late-phase osteoarthritis pipeline, based on clinical and commercial attractiveness - Overview of patient potential and unmet needs in osteoarthritis across the US, 5EU and Japanese markets - Identification of licensing opportunities based on company portfolios and market needs Highlights of this title: The key unmet need in osteoarthritis is disease modification. The early-phase pipeline is dominated by disease-modifying OA drugs (DMOADs), clearly indicating the future direction of the market. With the first DMOAD to market likely to reach blockbuster status, companies should strengthen their R&D potential by focusing efforts on DMOAD research. The issue of cardiovascular safety remains at the forefront of the COX-2 and traditional NSAID NSAID: see nonsteroidal anti-inflammatory drug. classes. As evidenced by Prexige (lumiracoxib) and Arcoxia (etoricoxib), appropriately designed, large-scale safety studies will be crucial if any COX-2s are to be approved by the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. and EMEA (Europe, Middle East, Africa) Refers to that region of the world. For example, one might see products packaged differently for the UK, EMEA and Asia Pacific markets. . Prexige and Arcoxia remain in pre-registration in the US. Over the next ten years a number of COX-2 inhibitors as well as NSAIDs and corticosteroids Corticosteroids Definition Corticosteroids are group of natural and synthetic analogues of the hormones secreted by the hypothalamic-anterior pituitary-adrenocortical (HPA) axis, more commonly referred to as the pituitary gland. , some with novel mechanisms of action and reportedly improved side effect profiles, will enter the market. Success will depend on effective but restrained marketing, product differentiation and strategic out-licensing arrangements. Reasons to order your copy: - Explore the potential of COX-2s such as Novartis' Prexige and Merck's Arcoxia in the osteoarthritis indication - Quantify the future size of and market potential for novel treatments in the osteoarthritis indication - Identify who the key players in the osteoarthritis market will be as well as understanding gaps in the market for potential products About Us HEALTHCARE 2 About the CNS See Continuous net settlement. CNS See continuous net settlement (CNS). , Arthritis and Pain pharmaceutical analysis team 2 Topics Covered: -Patient potential -R&d approach -Osteoarthritis pipeline analysis -Nsaid late-stage drug analysis & forecasts -Disease modifier (programming) modifier - An operation that alters the state of an object. Modifiers often have names that begin with "set" and corresponding selector functions whose names begin with "get". late-stage drug analysis -Analgesics late-stage drug analysis & forecasts -Corticosteroid late-stage drug analysis & forecasts -Innovative early-stage projects For more information, visit http://www.researchandmarkets.com/reports/c49689 Source: Datamonitor |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion